The stock of Replimune Group Inc (NASDAQ: REPL) has decreased by -2.84 when compared to last closing price of 6.33.Despite this, the company has seen a loss of -11.76% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-11 that The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
The stock has a 36-month beta value of 1.25. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for REPL is 44.47M, and at present, short sellers hold a 18.76% of that float. On April 26, 2024, the average trading volume of REPL was 1.29M shares.
REPL’s Market Performance
REPL stock saw a decrease of -11.76% in the past week, with a monthly decline of -20.03% and a quarterly a decrease of -22.05%. The volatility ratio for the week is 8.35%, and the volatility levels for the last 30 days are 6.12% for Replimune Group Inc (REPL).. The simple moving average for the past 20 days is -13.87% for REPL’s stock, with a -50.54% simple moving average for the past 200 days.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with Piper Sandler repeating the rating for REPL by listing it as a “Overweight.” The predicted price for REPL in the upcoming period, according to Piper Sandler is $44 based on the research report published on April 17, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $52. The rating they have provided for REPL stocks is “Overweight” according to the report published on November 19th, 2021.
BTIG Research gave a rating of “Buy” to REPL, setting the target price at $60 in the report published on October 15th of the previous year.
REPL Trading at -21.65% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.21% of loss for the given period.
Volatility was left at 6.12%, however, over the last 30 days, the volatility rate increased by 8.35%, as shares sank -25.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.05% lower at present.
During the last 5 trading sessions, REPL fell by -11.76%, which changed the moving average for the period of 200-days by -70.67% in comparison to the 20-day moving average, which settled at $7.03. In addition, Replimune Group Inc saw -27.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Xynos Konstantinos, who sale 7,313 shares at the price of $10.92 back on Nov 16 ’23. After this action, Xynos Konstantinos now owns 112,714 shares of Replimune Group Inc, valued at $79,858 using the latest closing price.
Sarchi Christopher, the Chief Commercial Officer of Replimune Group Inc, sale 5,255 shares at $10.92 during a trade that took place back on Nov 16 ’23, which means that Sarchi Christopher is holding 72,245 shares at $57,385 based on the most recent closing price.
Stock Fundamentals for REPL
The total capital return value is set at -0.46. Equity return is now at value -41.29, with -34.66 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.27. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -36.48.
Currently, EBITDA for the company is -177.4 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.40.
Conclusion
To sum up, Replimune Group Inc (REPL) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
